CRP and rheumatoid arthritis: In another multicenter study of RA patients with insufficient response to tocilizumab and other csDMARDs (MTX, SASP, and tacrolimus), the addition of IGU may be an effective complementary treatment, because outcome measures including DAS28-CRP and clinical disease activity index had been improved significantly and 51.6% RA patients achieved ACR 20 at 24 weeks (Table 2) (Ebina et al., 2019).